BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mirzaei S, Paskeh MDA, Okina E, Gholami MH, Hushmandi K, Hashemi M, Kalu A, Zarrabi A, Nabavi N, Rabiee N, Sharifi E, Karimi-Maleh H, Ashrafizadeh M, Kumar AP, Wang Y. Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention. J Exp Clin Cancer Res 2022;41:214. [PMID: 35773731 DOI: 10.1186/s13046-022-02406-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Devaraj A, Al-Sader H. Osteolytic lesions: Multiple myeloma or prostate cancer? Radiol Case Rep 2023;18:1485-9. [PMID: 36747906 DOI: 10.1016/j.radcr.2023.01.054] [Reference Citation Analysis]
2 Sadrkhanloo M, Paskeh MDA, Hashemi M, Raesi R, Motahhary M, Saghari S, Sharifi L, Bokaie S, Mirzaei S, Entezari M, Aref AR, Salimimoghadam S, Rashidi M, Taheriazam A, Hushmandi K. STAT3 signaling in prostate cancer progression and therapy resistance: An oncogenic pathway with diverse functions. Biomedicine & Pharmacotherapy 2023;158:114168. [DOI: 10.1016/j.biopha.2022.114168] [Reference Citation Analysis]
3 Hashemi M, Etemad S, Rezaei S, Ziaolhagh S, Rajabi R, Rahmanian P, Abdi S, Koohpar ZK, Rafiei R, Raei B, Ahmadi F, Salimimoghadam S, Aref AR, Zandieh MA, Entezari M, Taheriazam A, Hushmandi K. Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: Revisiting molecular interactions. Biomedicine & Pharmacotherapy 2023;158:114204. [DOI: 10.1016/j.biopha.2022.114204] [Reference Citation Analysis]
4 Huang S, Zhang J, Wan H, Wang K, Wu J, Cao Y, Hu L, Yu Y, Sun H, Yu Y, Wang J, Chen F. Plasma extracellular vesicles microRNA-208b-3p and microRNA-143-3p as novel biomarkers for sudden cardiac death prediction in acute coronary syndrome. Mol Omics 2023. [PMID: 36723013 DOI: 10.1039/d2mo00257d] [Reference Citation Analysis]
5 Hashemi M, Mirdamadi MSA, Talebi Y, Khaniabad N, Banaei G, Daneii P, Gholami S, Ghorbani A, Tavakolpournegari A, Farsani ZM, Zarrabi A, Nabavi N, Zandieh MA, Rashidi M, Taheriazam A, Entezari M, Khan H. Pre-clinical and clinical importance of miR-21 in human cancers: Tumorigenesis, therapy response, delivery approaches and targeting agents. Pharmacol Res 2023;187:106568. [PMID: 36423787 DOI: 10.1016/j.phrs.2022.106568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Liang H, Tse ZTH. MR conditional prostate intervention systems and actuations review. Proc Inst Mech Eng H 2023;237:18-34. [PMID: 36458323 DOI: 10.1177/09544119221136169] [Reference Citation Analysis]
7 Zandieh MA, Farahani MH, Rajabi R, Avval ST, Karimi K, Rahmanian P, Razzazan M, Javanshir S, Mirzaei S, Paskeh MDA, Salimimoghadam S, Hushmandi K, Taheriazam A, Pandey V, Hashemi M. Epigenetic regulation of autophagy by non-coding RNAs in gastrointestinal tumors: Biological functions and therapeutic perspectives. Pharmacol Res 2023;187:106582. [PMID: 36436707 DOI: 10.1016/j.phrs.2022.106582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wang Z, Liu J, Yang Q, Ma M. LncRNA MIAT Upregulates NEGR1 by Competing for miR-150-5p as a Competitive Endogenous RNA in SCIRI Rats. Int J Genomics 2022;2022:2942633. [PMID: 36620092 DOI: 10.1155/2022/2942633] [Reference Citation Analysis]
9 Xu J, Xu Y, Ye G, Qiu J. LncRNA-SNHG1 promotes paclitaxel resistance of gastric cancer cells through modulating the miR-216b-5p-hexokianse 2 axis. J Chemother 2022;:1-12. [PMID: 36548909 DOI: 10.1080/1120009X.2022.2157618] [Reference Citation Analysis]
10 Zhang C, Zhou Y, Zhang B, Sheng Z, Sun N, Yuan B, Wu X. Identification of lncRNA, miRNA and mRNA expression profiles and ceRNA Networks in small cell lung cancer.. [DOI: 10.21203/rs.3.rs-2209373/v1] [Reference Citation Analysis]
11 Ma Y, He X, Di Y, Liu S, Zhan Q, Bai Z, Qiu T, Corpe C, Wang J. Identification of prognostic immune-related lncRNAs in pancreatic cancer. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1005695] [Reference Citation Analysis]
12 Wu W, Wang S, Zhang L, Mao B, Wang B, Wang X, Zhao D, Zhao P, Mou Y, Yan P. Mechanistic studies of MALAT1 in respiratory diseases. Front Mol Biosci 2022;9. [DOI: 10.3389/fmolb.2022.1031861] [Reference Citation Analysis]
13 Hashemi M, Arani HZ, Orouei S, Fallah S, Ghorbani A, Khaledabadi M, Kakavand A, Tavakolpournegari A, Saebfar H, Heidari H, Salimimoghadam S, Entezari M, Taheriazam A, Hushmandi K. EMT mechanism in breast cancer metastasis and drug resistance: Revisiting molecular interactions and biological functions. Biomedicine & Pharmacotherapy 2022;155:113774. [DOI: 10.1016/j.biopha.2022.113774] [Reference Citation Analysis]
14 Hashemi M, Hasani S, Hajimazdarany S, Mirmazloomi SR, Makvandy S, Zabihi A, Goldoost Y, Gholinia N, Kakavand A, Tavakolpournegari A, Salimimoghadam S, Nabavi N, Zarrabi A, Taheriazam A, Entezari M, Hushmandi K. Non-coding RNAs targeting notch signaling pathway in cancer: From proliferation to cancer therapy resistance. International Journal of Biological Macromolecules 2022. [DOI: 10.1016/j.ijbiomac.2022.09.203] [Reference Citation Analysis]
15 Toury L, Frankel D, Airault C, Magdinier F, Roll P, Kaspi E. miR-140-5p and miR-140-3p: Key Actors in Aging-Related Diseases? IJMS 2022;23:11439. [DOI: 10.3390/ijms231911439] [Reference Citation Analysis]
16 Ye Q, Li L, Shao Z, Xu M, Li L, Yan Q, Huang B, Zhao T. Association between lncRNAs in plasma exosomes and diabetic retinopathy. Front Endocrinol 2022;13:987488. [DOI: 10.3389/fendo.2022.987488] [Reference Citation Analysis]
17 Entezari M, Taheriazam A, Orouei S, Fallah S, Sanaei A, Hejazi ES, Kakavand A, Rezaei S, Heidari H, Behroozaghdam M, Daneshi S, Salimimoghadam S, Mirzaei S, Hashemi M, Samarghandian S. LncRNA-miRNA axis in tumor progression and therapy response: An emphasis on molecular interactions and therapeutic interventions. Biomed Pharmacother 2022;154:113609. [PMID: 36037786 DOI: 10.1016/j.biopha.2022.113609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Guo Y, Feng L. N6-methyladenosine-mediated upregulation of LINC00520 accelerates breast cancer progression via regulating miR-577/POSTN axis and downstream ILK/AKT/mTOR signaling pathway. Arch Biochem Biophys 2022;:109381. [PMID: 36027936 DOI: 10.1016/j.abb.2022.109381] [Reference Citation Analysis]
19 Hajipour M, Mokhtari K, Mahdevar M, Esmaeili M, Peymani M, Nasr-Esfahani MH, Mirzaei S, Hasehmi M, Hushmandi K, Ghaedi K. Identification of a novel interplaying loop of PPARγ and respective lncRNAs are involved in colorectal cancer progress. Int J Biol Macromol 2022;219:779-87. [PMID: 35940433 DOI: 10.1016/j.ijbiomac.2022.07.247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]